Marquez-Rodas, I., Dutriaux, C., Saiag, P., Merino, L. D. L. C., Alvarez, E. C., Robert, C., Rodríguez-Moreno, J. F., Arance, A., Cerezuela-Fuentes, P., Montaudie, H., Sanmamed, M. F., González-Cao, M., Charles, J., Criado, M. P. L., Berrocal, A., Miguel, E. D., Funck-Brentano, E., Prey, S., Gala, M. C. Ã. D. L., Melero, I., Avilés-Izquierdo, J. A., Román, R., Garcia-Pelaez, B., Rodriguez, S., Trnkova, Z. J., Quintero, M., Macia, S., Chaney, M. F., Dalle, S. (2025). Erratum: BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-01680